Abstract: The methods and results of a set of cost-utility analyses conducted for the NICE Non-Alcoholic Fatty Liver Disease (NAFLD) and Cirrhosis guidelines, which were published in July 2016. These Markov models cover various diagnostic, and surveillance questions, including who should be tested, with which test and how frequently.
Cohorts included NAFLD, alcoholic liver disease, hepatitis B and hepatitis C. This presentation will focus on people with or at risk of NAFLD. The discussion will touch upon:
• The complexity of disease pathway modelling
• Interaction between patient choice and the results of cost-effectiveness analysis
• Incorporation of multiple NICE Single Technology Appraisals in to a clinical guideline model.
Biography: Having an academic background in economics and healthcare management, Lefteris has spent his career so far between providing methodological support to researchers applying for NIHR funding and developing national clinical guidelines primarily in the areas of liver disease and prisons’ healthcare.